New insulins and other possible therapeutic approaches

Zinman B, Tildesley H, Chiasson JH, Tsui E, Strack T (1997) Insulin lispro in CSII: Results of a double-blind crossover study. Diabetes 46: 440–443 Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn’t. BMJ 312: 71–72 Young AA, Wang MW, Gedulin B, Rink TJ, Pittner R, Beaumont K (1995) Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity. Metabolism 44: 1581–1589 Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A (1996) Effect of 14 days’ subcutaneous administration of the human amylin analogue, pramlintide (AC 137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 39: 492–499 Thompson RG, Pearson L, Gottlieb A, Kolterman OG (1996) Pramlintide, an analog of human amylin, reduced fructosamine in patients with type 1 diabetes. Diabetes 45: [Suppl 2] 222A (Abstract) Wahren J, Johansson B-L, Wallberg-Henriksson H, Linde B, Fernqvist-Forbes E, Zierath J R (1996) C-peptide revisited — new physiological effects and therapeutic implications. J Int Med 240: 115–124 Zenobi PD, Glatz Y, Keller A et al. (1994) Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin resistant diabetes type A. Eur J Endocrinol 131: 251–257 Dunger DB, Cheetham TD, Crowne EC (1995) Insulin growth factors (IGFs) and IGFI treatment in the adolescent with insulin-dependent diabetes mellitus. Metabolism 44: 119–123 Moses AC, Young SC, Morrow LA, O’Brien M, Clemmons DR (1996) Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycaemic control in type II diabetes. Diabetes 45: 91–100 Mitragotri S, Blankschtein D, Langer R (1995) Ultrasound-mediated transdermal protein delivery. Science 269: 850–853